Vaccine Development: From Antigen Design to Regulatory Approval

Exploring a streamlined view of the vaccine development process, from antigen discovery to regulatory approval, showcasing how genomics, AI, and automation accelerate target identification and production. The workflow is guided by stringent GMP compliance and robust QA/QC systems, ensuring vaccines are safe, effective, and ready for global distribution.

Key Takeaways

  • Vaccine development follows a step-by-step process, from identifying a target antigen and producing the vaccine component to testing, manufacturing, and regulatory approval.
  • Modern technologies such as genomics, proteomics, structural biology, and AI help scientists identify and validate the best vaccine targets more quickly and accurately.
  • Automation, high-throughput screening, and advanced protein production and purification tools speed up vaccine development while improving consistency and scalability.
  • Strict quality control, GMP manufacturing, and regulatory review are essential to ensure vaccines are safe, effective, and approved for use.

Immunization is one of the most impactful medical interventions, substantially reducing infectious disease burden worldwide. Since Jenner’s smallpox vaccine in 1796, vaccinology has advanced through multiple technological paradigms1. In 2024, the World Health Organization (WHO) estimated that vaccines prevent 2–5 million child deaths annually.2 Vaccines’ benefits extend beyond the individual to the wider community through reduced pathogen transmission. In addition to preventing mortality, they reduce morbidity and disability, delivering substantial economic benefits by alleviating poverty and addressing health inequities.3 Vaccination goals are evolving beyond infectious disease prevention toward broader therapeutic applications. Modern vaccine platforms aim to develop universal protection against rapidly mutating viruses such as influenza and coronaviruses, while expanding into areas including oncology, chronic infections, and non-communicable diseases. Personalized cancer vaccines, immune modulation, and vaccines targeting HIV, hepatitis B, and tuberculosis are being investigated.4

Recent advances in viral vaccine development include four key platforms:

  • Subunit vaccines – Use selected viral components; safe but may require adjuvants.
  • Protein-based vaccines – Use purified proteins; specific but less effective against mutations.
  • Reverse vaccinology (RV) – Uses genomic data to rapidly identify targets.
  • mRNA vaccines – Encode antigens in host cells; highly immunogenic but require strict storage conditions.5

Each year, over one billion vaccine doses are administered globally, primarily to healthy individuals, necessitating stringent standards for safety and quality. Reliable vaccine manufacturing is supported by four key competencies:

  • Manufacturing process – Defines how the vaccine is produced.
  • Organizational compliance – Ensures adherence to established procedures.
  • Product and process testing – Confirms quality, safety, and consistency.
  • Regulatory authorization – Governs product release and distribution.6

Workflow Title

Workflow description

View References
  1. Pawar B et al. A Comprehensive Review of Vaccine Development: From Traditional Platforms to Messenger RNA (mRNA) Technologies. Cureus, 2026. 18(1): e100608. DOI 10.7759/cureus.100608.
  2. Kim JH and Ndembi N. Global vaccine development. Nature Medicine. Volume 32, 2026:1610–1622. https://doi.org/10.1038/s41591-026-04384-9.
  3. Lopez SMC et al. Chapter 56 - Vaccines: An overview. 2023. https://doi.org/10.1016/B978-0-323-85730-7.00015-1
  4. Pawar N et al. Recent Trends in Vaccine Development. Int. J. of Pharm. Sci., 2025, Vol 3(11), 892-947. DOI: 10.5281/zenodo.17542939.
  5. Kumar A et al. Advancements in viral vaccine development: from traditional to modern approaches. Explor Immunol. 2025;5:1003203. https://doi.org/10.37349/ei.2025.1003203.
  6. Gomez LP et al. Vaccine manufacturing. Section 1: General aspects of vaccination. 2008. https://doi.org/10.1016/B978-1-4160-3611-1.50008-8
  7. Sette A and Rappuoli R. Reverse Vaccinology: Developing Vaccines in the Era of Genomics. Immunity 33, 2010. DOI: 10.1016/j.immuni.2010.09.017.
  8. Leddy OK et al. Leveraging Immunopeptidomics To Study and Combat Infectious Disease. mSystems 6:e00310-21. 2021. https://doi.org/10.1128/mSystems.00310-21.
  9. Michalik M et al. An Update on "Reverse Vaccinology": The Pathway from Genomes and Epitope Predictions to Tailored, Recombinant Vaccines. Methods Mol Biol. 2022:2412:45-71. DOI: 10.1007/978-1-0716-1892-9_4.
  10. Zhao M et al. Affinity chromatography for vaccines manufacturing: Finally ready for prime time? Vaccine. 2018. https://doi.org/10.1016/j.vaccine.2018.02.090.
  11. He X. Enhancing Viral Vaccine and Vector Manufacturing through Chromatographic Process Optimization. J Chromatogr Sep Tech, 2024. Vol.15 Iss.2 No:1000558.
  12. Morefield GL. A Rational, Systematic Approach for the Development of Vaccine Formulations. The AAPS Journal, Vol. 13, No. 2, 2011. DOI: 10.1208/s12248-011-9261-1.
  13. Lebar et al. Alternative buffer systems in biopharmaceutical formulations and their effect on protein stability. Acta Pharm. 74 (2024) 479–493. https://doi.org/10.2478/acph-2024-0022.
  14. Stability of vaccines and reference preparations, World Health Organization.
  15. Annex 3 - Guidelines on stability evaluation of vaccines. WHO Technical Report Series No. 962, 2011.
  16. Khan MDFH et al. Freeze-Drying of mRNA-LNPs Vaccines: A Review. Vaccines 2025, 13,853. https://doi.org/10.3390/vaccines13080853.
  17. Madukwe JC. Recent advancements in vaccine research and development. Trends in Pharmacological Sciences, 2024, Vol. 45(12). https://doi.org/10.1016/j.tips.2024.11.004.
  18. Matsuo K et al. Frontiers of transcutaneous vaccination systems: Novel technologies and devices for vaccine delivery. Vaccine 31. 2013. 2403–2415. http://dx.doi.org/10.1016/j.vaccine.2013.03.022.
  19. Kulhaadi RK. Quality Assurance (QA) for Vaccines: A Critical Pillar of Public Health Safety. Anna. Clin. Trai. Vacci. Res. 2024. 14(6), 298-299.
  20. Centers for Disease Control and Prevention (CDC) – How Vaccines Are Developed and Approved
    https://www.cdc.gov/vaccines/basics/how-developed-approved.html
  21. Pardi et al. mRNA vaccines: a new era in vaccinology. Nature Reviews Drug Discovery. 2018.
  22. Singh & Mehta. The clinical development process for a novel preventive vaccine. Journal of Postgraduate Medicine. 2016.
  23. World Health Organization (WHO) – Vaccine Manufacturing and Supply
    https://www.who.int/teams/immunization-vaccines-and-biologicals
  24. Seo & Song. Advancements and challenges in next-generation mRNA vaccine manufacturing systems. Clinical and Experimental Vaccine Research. 2025.
  25. WHO. Global Vaccine Market Report.
  26. Biology LibreTexts – Protein Purification
    https://bio.libretexts.org
  27. Lee. A Simple Outline of Methods for Protein Isolation and Purification. Endocrinology and Metabolism. 2017.
  28. Jakubowski & Flatt. Fundamentals of Biochemistry. Biology LibreTexts. 2026.
  29. U.S. Food and Drug Administration (FDA) – Vaccine Development – 101
    https://www.fda.gov/vaccines-blood-biologics
  30. Centers for Disease Control and Prevention (CDC) – Vaccine Trial Phases
    https://www.cdc.gov
  31. Singh & Mehta. Journal of Postgraduate Medicine. 2016.
  32. Chen et al. Nanotechnology-based mRNA vaccines. Nature Reviews Methods Primers. 2023.
  33. Papadatou & Michos. Advances in Biotechnology and the Development of Novel Human Vaccines. Vaccines (MDPI). 2025.
  34. Pardi et al. Nature Reviews Drug Discovery. 2018.

FAQ on Vaccine Development

How long does it take to formulate a vaccine?

Formulation takes months to several years, depending on the platform. Conventional vaccines often require 1–3 years during preclinical and early clinical development. Newer approaches, such as mRNA, speed up initial formulation, but stability, storage conditions, and manufacturing compatibility still need to go through validation before large-scale production.20,21,22

What are the main challenges of large‑scale vaccine production?

Large‑scale vaccine production is challenged by biological complexity, quality control, regulatory compliance, and global supply‑chain constraints. Because vaccines are produced using living systems or biologically active components, maintaining batch‑to‑batch consistency is critical. In addition, many vaccines require strict cold‑chain conditions, which complicate global distribution. Manufacturing capacity, access to raw materials, and harmonization of regulatory standards further affect scalability.

23,24,25

How is protein purification done?

Protein purification isolates a target protein while preserving its structure and activity. The process starts with cell lysis and clarification, followed by chromatographic steps such as affinity, ion exchange, or size exclusion. Process conditions depend on protein properties like size and charge. High purity is essential for vaccine antigen performance and safety.26,27,28

How do vaccine clinical trials work?

Clinical trials run in four phases.

  • Phase I assesses safety and immune response in a small group of healthy volunteers.
  • Phase II evaluates dosage and safety in hundreds of participants.
  • Phase III confirms efficacy and detects rare events in large populations.
  • Phase IV monitors safety after approval.
Each phase must meet regulatory criteria before progression.29,30,31

What new vaccine technologies are being explored?

Current vaccine research is focusing on mRNA vaccines, viral vector vaccines, virus‑like particles (VLPs), and nanoparticle‑based delivery systems. Additional innovations include self‑amplifying RNA, thermostable formulations, and mucosal or transdermal delivery to improve immune responses and global accessibility. These technologies enable faster vaccine design, improved immune targeting, and greater adaptability to emerging infectious diseases.32,33,34

Basse Hofzumahaus 

Basse Hofzumahaus 

Product Marketing Manager 

About the author:

Basse Hofzumahaus brings 15+ years of experience in life sciences, across academia, R&D, and product management. With a PhD and M.Sc. in Biotechnology, he connects scientific depth with a focus on upstream bioprocessing, microbial fermentation, CHO workflows, clone screening, and microbioreactor development.